Valuation dashboard for Pulmonx Corporation (LUNG) with P/E N/A, P/B 2.28, EV/EBITDA -2.18 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System.
Analysis Summary
Pulmonx Corporation reported revenue of $90.5M in the most recent fiscal year, growing at a 5-year CAGR of 22.6%.
Trailing-twelve-month margins: gross margin 77.1%, operating margin -53.0%, net margin -55.0%.
At the current price of $2.07, LUNG has negative trailing earnings (P/E not meaningful) and an ROE of -96.66%. Market capitalisation stands at $87M.
Balance sheet quality for LUNG: current ratio of 5.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.28 |
| EV / EBITDA | -2.18 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-8.64 |
| vs Current Price | -517.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LUNG | Pulmonx Corporation | $87M | 2.28 | -96.7% | |
| ABT | Abbott Laboratories | $177.5B | 33.03 | 3.50 | 10.5% |
| 0Y6X.L | Medtronic Plc | $124.2B | |||
| MDT | Medtronic plc | $117.9B | 22.29 | 2.32 | 10.6% |
| SYK | Stryker Corporation | $105.5B | 27.82 | 4.33 | 16.4% |
| 0R2S.L | Stryker Corporation | $103.6B | 28.10 | 4.37 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $64.5B | 47.43 | 5.68 | 11.9% |
| BSX | Boston Scientific Corporation | $64.4B | 17.49 | 2.57 | 14.9% |
Price
| Price | $2.07 |
| Market Cap | $87M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -96.66% |
| Return on Invested Capital | -48.39% |
| Return on Assets | -41.94% |
| Gross Margin | 77.06% |
| Operating Margin | -52.96% |
| Net Margin | -55.03% |
Related companies: ACRV · ASRT · EDAP · HYPR · IMUX · PMVP · RLMD
Explore sector: Healthcare · Medical - Devices
More sections of LUNG: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks